Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial

Carlo Pozzilli, Luca Prosperini, Silvia Tommasin, Claudio Gasperini, Elena Barbuti and Laura De Giglio

Abstract
Objective: To evaluate baseline characteristics predictive of improving information processing speed in multiple sclerosis (MS) and the relationship between cognitive and motor response to dalfampridine (DA) treatment.
Methods: This is a post hoc analysis of a randomized, double-blind, placebo-controlled trial in patients with MS randomized to receive DA 10 mg or placebo twice daily for 12 consecutive weeks. Here, we include only data from 71 patients in the arm treated with DA. According to the median value of Symbol Digit Modalities Test (SDMT) response, patients were categorized as “full responders” (FR) or “partially responders” (PR).
Results: There was higher possibility of being FR in the presence of a baseline lower Expanded Disability Status Scale (OR 0.69; 95% confidence interval [CI] 0.5–0.97, p = 0.034), a higher Multiple Sclerosis Functional Composite value (OR 1.37; 95%CI 1.05–1.8, p = 0.022), a lower Timed 25-Foot Walk Test (OR 0.76; 95% CI 0.6–0.98, p = 0.033), and a lower 9-Hole Peg Test with dominant hand (OR 0.92; 95% CI 0.86–0.99, p = 0.029). FR group did not show any significant improvement of motor performance compared with PR group.
Conclusion: The current analysis shows that in MS patients with cognitive deficit, the greatest improvement in SDMT provided by DA was observed in patients with milder motor impairment; cognitive and motor responses to treatments are not related.
Trial registration: EU Clinical Trials Register; ID 2013-002558-64 (https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002558-64)

Keywords: dalfampridine, multiple sclerosis, processing speed, response to treatment

Introduction
Dalfampridine (DA) has been shown to improve walking ability in a subset of patients with multiple sclerosis (MS).1,2 More recent experiences with DA showed that benefits to MS patients may be broader than just on walking speed, with improvements in gait pattern, manual dysfunction, walking endurance, balance, fatigability, cognitive dysfunction and quality of life.3–12 Recently, we demonstrated in a randomized, double-blind, placebo-controlled trial the efficacy of DA treatment in improving information processing speed in patients with MS and a documented deficit in this cognitive domain.13 This was the only randomized, double-blind, placebo-controlled trial of class I which demonstrated the cognitive efficacy of DA with a medium effect size.14 Proper selection of patients experiencing...
clinical benefits in Symbol Digit Modalities Test (SDMT)\textsuperscript{15} from DA has not yet been reported. Therefore, here we report a post-hoc analysis aimed to test the predictive value of a set of demographic and clinical criteria baseline characteristics. Moreover, it is unknown whether the beneficial effects of DA on cognition are limited to patients showing poor SDMT response or extended to patients with deficit regarding motor function. This implies that responsiveness to DA should be evaluated in the clinical setting separately for cognitive and motor function.

Materials and methods

Patients and procedures

This post-hoc analysis included patients who received DA in the trial. The study design for the DA trial study has been previously reported.\textsuperscript{13} Briefly, this was a randomized, double-blind, placebo-controlled trial in which 120 patients with MS were randomized in a 2:1 ratio to receive DA 10 mg or placebo twice daily for 12 consecutive weeks.

The study was sponsored by an investigator initiated trial grant from Biogen, who reviewed the protocol and provided both DA and matching placebo.

We enrolled patients from two regional referral MS Centers in Rome from February 2015 to June 2016. Patients were referred to the trial in the clinics, based on their subjective cognitive complaints. Eligible participants were patients with a diagnosis of MS according to the revised McDonald criteria,\textsuperscript{16} with an age ranging from 18 to 65 years (inclusive) and a score in the SDMT below the 10th percentile of normative values of the Italian population.\textsuperscript{17,18} Exclusion criteria were: (1) the occurrence of a clinical relapse in the previous 60 days; (2) history of major depression or psychosis; (3) severe or moderate depression according to Beck Depression Inventory-II (with a cut-off score of 19);\textsuperscript{19,20} (4) history of seizures; (5) conditions that would interfere with study conduct; (6) introduction or modification of any medication including medication for mood, fatigue or cognition in the previous month. Eligible patients completed the whole cognitive battery, the clinical evaluation and other study questionnaires according to the study protocol. After 12 weeks patients came back to the Centers to repeat the tests.

Outcome measures

The main endpoint of efficacy–response to treatment was an improvement in the SDMT, calculated as the number of patients presenting at least an improvement of four points in the raw SDMT.

The administration of SDMT was preceded by a learning sequence at all time-points; furthermore, to reduce the learning effect, two alternative versions of the test were presented.\textsuperscript{15,17,21} Other outcomes of the study included the 9-Hole Peg Test (9HPT), the Timed 25-Foot Walk Test (T25-FWT) and the 3-s version of Paced Auditory Serial Addition Test (PASAT)\textsuperscript{22} seconds rate, which were used to calculate the Multiple Sclerosis Functional Composite (MSFC) score.\textsuperscript{23}

Statistical methods

Data management and analyses were performed on available data by an independent research organization (TFS Trial Form Support S.L., Rome, Italy) with no role in the study design and data collection. Previous results from the trial\textsuperscript{13} showed at the 12-week assessment a raw score increase in the SDMT from baseline of 9.9 [95% confidence interval (CI) 8.5–11.4] for patients treated with DA and of 5.2 (95% CI 2.8–7.6) for patients in the placebo group ($p = 0.0018$). In the present analysis, we included only data from patients in the arm treated with DA. Since the median value of improvement in treated patients at the SDMT performance at the end of the treatment period was 10 points, we chose this value as cut-off to categorize patients as “full responders” (FR) or “partially responders” (PR).

Statistical analyses were performed using Stata 14.2. Two-tailed $p$-values $<0.05$ were considered as significant.

We used a univariate logistic regression considering baseline characteristics to identify predictors of response. Moreover, to explore potential predictors of better response to DA, we ran a three-step hierarchical linear regression model (stepwise fashion) to identify which demographic variables (step 1), clinical factors (step 2) and motor and cognitive scores (step 3) were associated with
change in raw SDMT score from baseline assessment (dependent variable).

**Results**

Out of 120 randomized to receive DA \((n = 80)\) or placebo \((n = 40)\), 71 patients allocated to the DA group completed 12 weeks of treatment.

Briefly, the sample consisted of 41 women and 30 men with a mean ± standard deviation (SD) age of 49.1 ± 7.7 years, mean (SD) disease duration of 13.9 ± 8.6 years, mean SDMT raw score of 30.2 ± 7.8 and median (range) Expanded Disability Status Scale (EDSS) score of 3.5 (1.0–6.0). Of them, 63 had a relapsing–remitting, seven a secondary progressive and one a primary progressive phenotype; 45 were on-treatment and the remaining 26 were off-treatment with disease-modifying drugs (Table 1 reports baseline clinical characteristics for both FR and PR groups).

According to our definition, 34 patients were classified as FR and 37 as PR.

The FR group consisted of 23 women and 11 men with a mean age of 48.1 ± 7.2 years; in the PR group we found 18 females and 19 males with a mean age of 49.0 ± 8.2 years. We did not find differences between groups in baseline characteristics (Table 1) except for median EDSS, which was lower in FR group compared with PR \([3.0, \text{range } 1.5–4.5] \text{ versus } [4.0, \text{range } 3.0–5.0], \text{OR } 0.69; \text{95\% CI } 0.5–0.97, p = 0.034\).

The FR group also presented a better performance in MSFC \([0.79 ± 1.99] \text{ versus } [−0.40 ± 1.96]\) with a higher possibility of being FR in presence of a better MSFC value \((\text{OR } 1.37; \text{95\% CI } 1.05–1.8, p = 0.022)\); in particular FR group presented a lower T25-FWT and a lower 9HPT with dominant hand compared with PR group \([6.63 ± 1.86] \text{ versus } [8.04 ± 2.96]; \text{OR } 0.76; \text{95\% CI } 0.6–0.98,\)

### Table 1. OR of baseline clinical characteristics for dalfampridine responders.

|                | PR \(n = 37\) | FR \(n = 34\) | OR      | 95\% CI     | \(p\) |
|----------------|--------------|--------------|---------|-------------|------|
| **Gender, \(n(%)\)** |              |              |         |             |      |
| Male           | 19 (51.4)    | 11 (32.4)    | 1       |             |      |
| Female         | 18 (48.7)    | 23 (67.7)    | 2.21    | 0.8–5.8     | 0.108|
| **Age years, mean [SD]** | 49.0 [8.2] | 48.1 [7.2] | 1.00    | 0.9–1.1     | 0.924|
| **Formal education, mean [SD]** | 13.1 [3.5] | 12.5 [3.5] | 0.95    | 0.8–1.1     | 0.477|
| **Phenotypes, \(n(%)\)** |              |              |         |             |      |
| Relapsing remitting | 34 (91.9)  | 29 (85.3)    | 1       |             |      |
| Secondary progressive | 3 (8.1)    | 4 (11.8)    | 1.56    | 0.3–7.6     | 0.579|
| Primary progressive | 0 (0.0)     | 1 (2.9)     |         |             |      |
| **Patients under DMT, \(n(%)\)** |              |              |         |             |      |
| No             | 13 (35.1)    | 13 (38.2)    | 1       |             |      |
| Yes            | 24 (62.2)    | 21 (61.8)    | 0.91    | 0.3–2.4     | 0.854|
| **Disease duration, years, mean [SD]** | 15.2 [8.0] | 12.5 [9.0] | 0.96    | 0.9–1.0     | 0.179|
| **EDSS, median [range]** | 4 [3–5]   | 3 [1.5–4.5] | 0.69    | 0.5–0.97    | 0.034|

\(p\) values refer to univariate logistic regression. CI, confidence interval; DMT, disease modifying treatment; EDSS, Expanded Disability Status Scale; FR, fully responders; OR, odds ratio; PR, partially responders.
Univariate and multivariable hierarchical linear regression models predicting change in SDMT score at week 12 in patients treated with dalfampridine (\( n = 71 \)) are shown in Table 3. The strongest predictor of univariate linear regression was 9HPT dominant hand. (\( p = 0.011 \)). The hierarchical linear regression model did not reveal any demographic variable (step 1) predicting the outcome. The introduction of baseline clinical variables (step 2) revealed that the EDSS score contributed significantly to the regression equation (\( F_{1,69} = 4.10, \ p = 0.047 \)), although explaining only 5\% of the variance in outcome. Finally, entering in the model the baseline motor and cognitive scores (step 3) revealed other significant independent predictors (9HPT dominant hand, SDMT and PASAT) that explained 24\% of the variance in outcome, and this \( R^2 \)-change was significant (\( F_{1,63} = 4.83, \ p = 0.032 \)).

In Table 3, mean changes from baseline of 9HPT dominant hand, 9HPT no dominant hand and T25-FWT are reported for patients PR and FR to DA treatment. FR group did not show any significant improvement of motor performance compared with PR group. Mean changes of SDMT from baseline were not different comparing two groups of patients as divided according to their response to measures of motor functions (data not shown).

Discussion

The mechanisms underlying the observed changes in responsiveness of DA remain speculative.

A neurophysiological study suggests that patients with MS with a normal pre-therapy central motor conduction time (CMCT) are very unlikely to benefit from DA, whereas patients with a prolonged CMCT have a higher chance to respond to treatment.\(^{24}\) Given that DA may improve signal conduction by blocking potassium channels along demyelinated axons, patients with extensive demyelination might benefit more from this treatment. In addition to that, in experimental models, Dietrich et al.\(^{25}\) demonstrated that 4-aminopyridine could prevent axonal loss.

Few attempts have aimed to predict clinical responsiveness to DA in MS patients. Some studies provide evidence that walking function at baseline can accurately predict the responder status, patients more disabled at baseline having the best outcome.\(^{26-28}\) On the other hand, original works by Goodman et al.,\(^1,2,29\) as well as work by Allart et al.,\(^3\) showed that responders and non-responders had similar baseline characteristics.

In our study the positive effect of DA on processing speed was specific to the primary outcome of SDMT. Patients were recruited based on a specific impairment in processing speed, while the impairment in other domains was not necessary. Therefore, processing speed impairment in MS should be associated with higher amount of axonal demyelination within the neural cognitive

\( p = 0.033 \) and 22.97 ± 6.33 \textit{versus} 29.26 ± 14.25, OR 0.92; 95\% CI 0.86–0.99, \( p = 0.029 \) (Table 2).
network, providing more targets for DA to reinforce processing speed.

In the present study, EDSS score, as well as motor functions (T25-FWT and 9HPT), predicted improvement in information processing speed by DA. The strongest predictor in the univariate analysis was 9HPT in dominant hand, indicating the best response in patients with preserved manual abilities. Lower EDSS value and

### Table 3. Univariate and multivariable hierarchical linear regression models predicting change in SDMT score at week 12 in patients treated with dalfampridine (n=71).

|                        | β     | 95% confidence intervals | p-value | Adjusted $R^2$ |
|------------------------|-------|--------------------------|---------|----------------|
|                        |       | Lower bound              | Upper bound |       |
| **Univariate analysis**|       |                          |          |               |
| Sex (male versus female) | 1.45  | −1.43                    | 4.34     | 0.32          |
| Age (each year)        | 0.02  | −0.17                    | 0.20     | 0.86          |
| Formal education (≤13 versus >13 years) | 0.32  | −3.11                    | 3.76     | 0.85          |
| Disease duration (each year) | −0.07 | −0.23                    | 0.10     | 0.43          |
| Phenotype (SP/PP versus RR) | 0.99  | −3.54                    | 5.52     | 0.66          |
| EDSS score (each step) | −0.98 | −1.94                    | −0.02    | 0.047         |
| DMT exposure (yes versus no) | −0.63 | −3.60                    | 2.35     | 0.68          |
| T25-FWT (each second)  | −0.58 | −1.14                    | −0.01    | 0.047         |
| 9HPT dominant hand (each second) | −0.16 | −0.28                    | −0.04    | 0.011         |
| 9HPT non-dominant hand (each second) | −0.15 | −0.29                    | −0.01    | 0.044         |
| SDMT (each point)      | −0.07 | −0.26                    | 0.12     | 0.47          |
| PASAT (each point)     | 0.11  | 0.01                     | 0.22     | 0.048         |
| **Multivariable hierarchical analysis** |       |                          |          |               |
| **Step 1**             |       |                          |          |               |
| No predictors          |       |                          |          |               |
| **Step 2**             |       |                          |          | 0.05          |
| Constant               | 13.61 | 9.86                     | 17.36    | <0.001        |
| EDSS score (each step) | −1.11 | −2.12                    | −0.10    | 0.033         |
| **Step 3**             |       |                          |          | 0.24          |
| Constant               | 22.44 | 14.50                    | 30.39    | <0.001        |
| 9HPT dominant hand (each second) | −0.30 | −0.48                    | −0.12    | 0.001         |
| SDMT (each point)      | −0.27 | −0.47                    | −0.07    | 0.01          |
| PASAT (each point)     | 0.13  | 0.01                     | 0.26     | 0.032         |

9HPT, 9-Hole Peg Test; DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; PASAT, Paced Auditory Serial Addition Test; PP, primary progressive; RR, relapsing-remitting; SDMT, Symbol Digit Modalities Test; SP, secondary progressive; T25-FWT, Timed 25-Foot Walk Test.
better performance at T25-FWT were also predictive of a good response.

Patients with an impairment of information processing speed, as those enrolled in the present study, showed lower deep gray matter volume, less white matter integrity, but also stronger increases in functional connectivity.30 EDSS had a direct linear relationship with lesion load and inverse of thalamic volume, while it benefitted from functional connectivity, representing mechanisms of adaptation to structural damage and inflammation.31 Although it is quite difficult to apply cut-offs of EDSS to individual patients, functional connectivity generally decreases in comparison with structural measure at EDSS score greater than 3.0, which may be critical and indicate exhaustion of compensatory mechanisms.31 Similarly, it has been demonstrated that impaired finger dexterity in MS is associated with a decreased functional connectivity in several regions involved in motor functions such as superior frontal gyrus, lingual gyrus and posterior cerebellum.32 In our patients, a poor response should reflect failure of functional connectivity, interfering with the action of DA, which primarily involves an enhanced conduction in demyelinated pathways.

An interesting issue, also emerging from the present study, is that the motor response to DA is similar in FR and PR at SDMT, corroborating the hypothesis of different networks involving motor control and sustained attention. Correlations between functional connectivity clinical and neuropsychological variables in MS showed that a higher EDSS score correlated with a maladaptive neuronal response in the supplementary motor area bilaterally and in the right precentral operculum,33 as well as with a more rigid (less fluid) global connectivity.34 Conversely, temporal network and relay areas the cerebellum and brainstem correlated with cognitive performances.34–36 Prosperini et al.11 in a sub-study of the present trial demonstrated that patients classified as responders to DA according to SDMT improved also their postural sway, thus confirming the hypothesis of an overlap between the two networks connecting balance and information processing speed.37,38

A limitation of this post hoc study is that PR and FR subgroups were defined retrospectively. The similar sample size of the two subgroups PR \( n = 37 \) and FR \( n = 34 \), however, may enhance statistical comparisons.

**Conclusion**
We have previously demonstrated that DA administered for 12 weeks improves information processing speed in patients with MS showing poor SDMT performance; here we found that favored response is extended to patients with motor deficit. However, a greater response to DA was observed only in a subpopulation of patients who had a lower EDSS and a better performance on tests of walking and hand dexterity. A maladaptive structural and functional plasticity in more motor disabled patients might account for these findings. These findings could help us to select the best candidate for DA treatment, even though further studies are required to confirm our hypothesis and to explore other predictors of treatment response.

**Acknowledgements**
Authors of this article meet all the four International Committee of Medical Journal Editors (ICMJE) criteria for authorship, take responsibility and are accountable for the work. All authors have given their approval for this version of the article to be published.
Conflict of interest statement
CP reports: scientific advisory boards for Actelion, Biogen, Genzyme, Hoffmann-La Roche, Merck-Serono, Novartis, Sanofi and Teva; consulting and/or speaking fees, research support and travel grants from Allergan, Almirall, Biogen, Genzyme, Hoffmann-La Roche, Merck-Serono, Novartis, Sanofi and Teva. LP reports: consulting fees from Biogen, Novartis and Roche; speaker honoraria from Biogen, Genzyme, Merck Serono, Novartis and Teva; travel grants from Biogen, Genzyme, Novartis and Teva; research grants from the Italian MS Society (Associazione Italiana Sclerosi Multipla) and Genzyme. ST has nothing to disclose. CG reports: fees as invited speaker or travel expenses for attending meeting from Biogen, Merck-Serono, Teva, Sanofi, Novartis and Genzyme.

EB has nothing to disclose. LDG reports: travel grants from Biogen, Novartis and Teva.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by an investigator initiated trial (IIT) grant from Biogen (grant number CUP B8511700033000).

Ethics statement and informed consent
All procedures performed in the study were in accordance with the Helsinki Declaration as revised in 2013 or comparable ethical standards. The study was reviewed and approved by the Ethical Committee of Sapienza University in Rome (Prot. 1074/13, Rif. 2991/28.11.2013) and all patients signed an informed consent prior to any study-related procedure. The study was prospectively registered to the (2013-002558-64) EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/) with the ID 2013-002558-64).

ORCID iD
Carlo Pozzilli https://orcid.org/0000-0002-6360-4798

References
1. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494–502.
2. Goodman AD, Brown TR, Krupp LB, et al. Sustained release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732–738.
3. Allart E, Benoît A, Blanchard-Dauphin A, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol 2015; 262: 1936–1945.
4. Hupperts R, Lycke J, Short C, et al. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Mult Scler 2016; 22: 212–221.
5. Savin Z, Lejbkowicz I, Glass-Marmor L, et al. Effect of fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with multiple sclerosis. J Neurol Sci 2016; 360: 102–109.
6. Macdonell R, Nagels G, Laplaud DA, et al. Improved patient-reported health impact of multiple sclerosis: the ENABLE study of PR-fampridine. Mult Scler 2016; 22: 944–954.
7. Fragoso YD, Adoni T, Alves-Leon SV, et al. Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders. NeuroRehabilitation 2016; 39: 301–304.
8. Gasperini C, Hupperts R, Lycke J, et al. Prolonged-release fampridine treatment improved subject reported impact of multiple sclerosis: item-level analysis of the MSIS-29. J Neurol Sci 2016; 370: 123–131.
9. Morrow SA, Rosehart H and Johnson AM. The effect of fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Multi Scler Relat Disord 2017; 11: 4–9.
10. Broicher SD, Fili L, Geisseler O, et al. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol 2018; 265: 1016–1025.
11. Prosperini L, Castelli L, De Giglio L, et al. Dalfampridine to improve balance in multiple sclerosis: substudy from a randomized placebo-controlled trial. Neurotherapeutics 2020; 17: 704–709.
12. Rodriguez-Leal FA, Haase R, Akgün K, et al. Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting. Ther Adv Chronic Dis 2019; 10: 1–11.
13. De Giglio L, De Luca F, Gurrei F, et al. Effect of dalfampridine on information processing speed
impairment in multiple sclerosis. Neurology 2019; 93: 325–326.

14. Chen MH, Goverover Y, Genova HM, et al. Cognitive efficacy of pharmacologic treatments in multiple sclerosis: a systematic review. CNS drugs 2020; 34: 599–628.

15. Benedict RH, DeLuca J, Phillips G, et al.; Multiple Sclerosis Outcome Assessments Consortium. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 2017; 23: 721–733.

16. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

17. Amato MP, Portaccio E, Goretti B, et al. The Rao’s brief repeatable battery and stroop test: normative values with age, education and gender corrections in an Italian population. Mult Scler 2006; 12: 787–793.

18. Comi G, Patti F, Rocca MA, et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol 2017; 264: 2436–2449.

19. Ghisi M, Flebus GB, Montano A, et al. Beck depression inventory-II: Manuale italiano. Firenze: Giunti Organizzazioni Speciali, 2006.

20. Quaranta D, Marra C, Zinno M, et al. Presentation and validation of the multiple sclerosis depression rating scale: a test specifically devised to investigate affective disorders in multiple sclerosis patients. Clin Neuropsychol 2012; 26: 571–587.

21. Goretti B, Patti F, Cilia S, et al. The Rao’s brief repeatable battery version B: normative values with age, education and gender corrections in an Italian population. Neurol Sci 2014; 35: 79–82.

22. Rao SM and the Cognitive Function Study Group of the National Multiple Sclerosis Society. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. Milwaukee, WI: Medical College of Wisconsin, 1990.

23. Rudick RA, Polman CH, Choie JA, et al. Assessing disability progression with the multiple sclerosis functional composite. Mult Scler 2009; 15: 984–997.

24. Zeller D, Reiners K, Brauning S, et al. Central motor conduction time may predict response to fampridine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 707–709.

25. Dietrich M, Koska V, Hecker C, et al. Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain 2020; 143: 1127–1142.

26. Brambilla L, Rossi Sebastiano D, Aquino D, et al. Early effect of dalfampridine in patients with MS: a multi-instrumental approach to better investigate responsiveness. J Neurol Sci 2016; 368: 402–407.

27. Filli L, Zorner B, Kapitza S, et al. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. Neurology 2017; 88: 832–841.

28. Weller D, Lorincz L, Sutter T, et al. Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis. J Neurol Sci 2020; 416: 116978.

29. Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008; 71: 1134–1141.

30. Meijer KA, van Geest Q, Eijlers AJC, et al. Is impaired information processing speed a matter of structural or functional damage in MS? Neuroimage Clin 2018; 20: 844–850.

31. Tommasin S, De Giglio L, Ruggieri S, et al. Relation between functional connectivity and disability in multiple sclerosis: a non-linear model. J Neurol 2018; 265: 2881–2892.

32. Cordani C, Meani A, Esposito F, et al. Imaging correlates of hand motor performance in multiple sclerosis: a multiparametric structural and functional MRI study. Mult Scler 2020; 26: 233–244.

33. Zhou F, Zhuang Y, Gong H, et al. resting state brain entropy alterations in relapsing remitting multiple sclerosis. PLoS One 2016; 11: e0146080.

34. Lin F, Zivadinov R, Hagemeier J, et al. Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. Mult Scler 2019; 25: 1243–1254.

35. Van Geest Q, Douw L, van ’t Klooster S, et al. Information processing speed in multiple sclerosis: relevance of default mode network
dynamics. *Neuroimage Clin* 2018; 19: 507–515.

36. D’Ambrosio A, Valsasina P, Gallo A, *et al.* Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis. *Mult Scler* 2020; 26: 476–488.

37. Kalron A, Allali G and Achiron A. Cerebellum and cognition in multiple sclerosis: the fall status matters. *J Neurol* 2018; 265: 809–816.

38. Ruggieri S, Fanelli F, Castelli L, *et al.* Lesion symptom map of cognitive-postural interference in multiple sclerosis. *Mult Scler* 2018; 24: 653–662.